MedTrace Logo

Endocan Levels in Women With Premature Ovarian Insufficiency

NCT03924648 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 77

Last updated 2019-04-23

No results posted yet for this study

Summary

Objective: To evaluate serum endocan levels in women with premature ovarian insufficiency (POI) and to compare the results with those of healthy subjects.

Methods: This prospective study included 38 women with idiopathic POI and 39 controls. The blood for analysis was obtained at the early follicular phase of the menstrual cycle and serum endocan levels were measured using a commercially available ELISA kit. Follicle-stimulating hormone (FSH), estradiol, and anti-mullerian hormone (AMH) were measured at the same time. The continuous values were evaluated using Student's t-test, and categorical values were evaluated using the Chi-square test. P values \< .05 were accepted as significant.

Conditions

  • Premature Ovarian Failure

Interventions

OTHER

Endocan levels

Venous blood sample from the antecubital veins for measuring serum concentration of Endocan. The serum endocan level was measured using a commercially available ELISA kit, which is produced to detect human endocan levels with high sensitivity and specificity (Elabscience Biotechnology Inc., Houston, TX, USA). The endocan measurements were performed in accordance with company's protocol.

Sponsors & Collaborators

  • Cengiz Gokcek Women's and Children's Hospital

    lead OTHER

Principal Investigators

  • Ali Ovayolu, MD · Cengiz Gokcek WCH

Eligibility

Min Age
18 Years
Max Age
39 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-01
Primary Completion
2018-12-30
Completion
2019-04-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03924648 on ClinicalTrials.gov